Ditekiren
Also known as: Ro 42-5892, RO 425892
Source Ditekiren at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ditekiren is an investigational peptidomimetic renin inhibitor developed in the late 1980s and early 1990s. It was studied as an antihypertensive agent but never reached clinical approval. It demonstrated potent in vitro and in vivo renin inhibition and served as a key tool compound in validating renin as a therapeutic target, contributing to the later development of aliskiren.
Mechanism of Action
Competitive inhibitor of renin, the aspartyl protease that cleaves angiotensinogen to angiotensin I. By blocking renin, ditekiren reduces angiotensin I and II formation, lowering blood pressure via suppression of the renin-angiotensin-aldosterone system (RAAS).
Routes of Administration
Goals & Uses
- Blood pressure reductionCardiovascularModerate
- Renin inhibition (pharmacological probe)ResearchHigh
- RAAS characterizationResearchHigh
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Concurrent use with ACE inhibitors or ARBs in diabetic patientsDrug InteractionModerate
- Known hypersensitivity to ditekiren or excipientsAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Renal function impairmentRenalRare
- HyperkalemiaElectrolyte ImbalanceUncommon
Drug Interactions
- Angiotensin Receptor Blockers (ARBs)Moderate
- ACE inhibitorsModerate
- Potassium-sparing diureticsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with severe renal artery stenosisRenalAbsolute
- Pregnant womenReproductiveAbsolute
- Volume-depleted patientsCardiovascularRelative
Regulatory Status
- European UnionUnapprovedNever received EMA review; research compound only.
- United StatesUnapprovedNever submitted to FDA; research compound only.
- United KingdomUnapprovedNo MHRA submission; remains a research tool compound.
Ditekiren was never submitted for regulatory approval in any jurisdiction. It remains a research compound used primarily to characterize renin inhibitor pharmacology.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ditekiren?
Ditekiren is an investigational peptidomimetic renin inhibitor developed in the late 1980s and early 1990s. It was studied as an antihypertensive agent but never reached clinical approval. It demonstrated potent in vitro and in vivo renin inhibition and served as a key tool compound in validating renin as a therapeutic target, contributing to the later development of aliskiren.
What is Ditekiren used for?
Ditekiren is educationally associated with: Blood pressure reduction, Renin inhibition (pharmacological probe), RAAS characterization. Educational only — not medical advice.
How is Ditekiren administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Ditekiren?
Reported adverse effects include: Injection site reactions, Hypotension, Renal function impairment, Hyperkalemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ditekiren?
Recorded contraindications: Pregnancy, Concurrent use with ACE inhibitors or ARBs in diabetic patients, Known hypersensitivity to ditekiren or excipients. Consult a qualified clinician before use.